Posted by Michael Wonder on 01 Aug 2018
FDA approves blood disorder drug made by Japan's Shionogi
1 August 2018 - The U.S. FDA on Tuesday approved Japan-based Shionogi's treatment for low blood-platelet count or thrombocytopenia in patients with chronic liver disease.
The treatment belongs to a new class of drugs called thrombopoietin receptor agonists (TPO RA), which stimulate platelet production.
Its approval is the second for this class of drug for liver disease patients, following the FDA’s greenlight for U.S.-based Dova Pharmaceuticals’ rival treatment in May.
